

## **B. REMARKS**

Claims 1 to 56 are pending.

### **A. Regarding the Amendment**

Claim 1 has been amended to clarify that the topoisomerase “covalently links” both strands of the first and second ds nucleotide sequences. It is submitted that the amendment is supported by the language of claim 1 as originally filed, which specified “thereby generating a ds recombinant nucleic acid molecule covalently linked in both strands” (emphasis added) and, therefore, does not add new matter.

### **B. Regarding the Information Disclosure Statement**

It is noted that references WO 97/48716 and WO 98/56943 listed in a Form 1449 submitted with an Information Disclosure Statement on October 31, 2002, were not initialed by the Examiner as indicating that the references were submitted. For the Examiner's convenience, a copy of the previously submitted Form 1449 is attached (Attachment A). Applicants respectfully request that the Examiner consider these two cited references, and indicate such consideration by initialing the Form 1449 and returning it to Applicants' representative with the next Communication for this case. If there is any reason the references cannot be considered, it is respectfully requested that the Examiner contact Applicants' undersigned representative.

In addition, an Information Disclosure Statement and Form 1449 citing Sykes and Johnston is submitted herewith. Consideration of the reference is respectfully requested.

### **C. Prior Art Rejections**

The following remarks are made with respect to the final Office Action mailed August 17, 2004.

The rejection of claims 1 to 5, 8 to 10, 12 to 14, 25, 26, 28 to 31, 37 to 41, 44, 45, and 49 to 54 under 35 U.S.C. § 102(b) as allegedly anticipated by Shuman is respectfully traversed.

Shuman is cited as describing a method of generating a double stranded (ds) recombinant nucleic acid by contacting a first ds nucleotide sequence, a second ds nucleotide sequence, and a topoisomerase such that the topoisomerase covalently link both strands of the first sequence to the second sequence. Shuman describes methods for linking duplex DNA molecules using topoisomerase. Referring to Figure 5, Shuman shows a first ds nucleotide sequence having a topoisomerase bound to each 3' terminus ("topoisomerase charged bivalent linker"), and a second ds nucleotide sequence comprising a linearized vector (Hind III cleaved pUC18). Upon contact of the first and second ds nucleotide sequences shown in Figure 5, the 3' termini of the first ds nucleotide sequence (shown with the "T" topoisomerase) will be covalently linked to the 5' termini of the second ds nucleotide sequence (see, also, col. 7, lines 13-27). As such, the first ds nucleotide sequence is linked to the vector in one strand at each end, but not in the second strand of each end and, therefore, the recombinant molecule contains a nick where the two sequences were joined.

As discussed with the Examiner, the present claims recite that the topoisomerase covalently link both strands of at least one end of the first ds nucleotide sequence to both strands of at least one end of the second ds nucleotide sequence to obtain a recombinant ds nucleic acid molecule that "does not contain a nick in either strand at the position where the ds nucleotide sequences are joined". The generation of a ds recombinant nucleic acid molecule according to a method of the invention is exemplified in Figure 1B. For illustrative purposes, the Examiner's attention was referred to the left ("first") end of the "first" ds nucleotide sequence shown in the top panel of Figure 1B, in which a topoisomerase is shown bound to the 3' terminus of the first

end of the first ds nucleotide sequence; and was further directed to the right ("first") end of the "second" ds nucleotide sequence shown as "Element1" in the middle panel of Figure 1B, in which a topoisomerase is bound to the 3' terminus of the first end of the second ds nucleotide sequence. As shown in the third panel of Figure 1B, contact of the first end of the first ds nucleotide sequence and the first end of the second ds nucleotide sequence results in covalent linkage of both strands of the first ends, thereby generating a ds recombinant nucleic acid molecule that does not contain a nick at the joined "first ends". As such, the claimed invention is distinguishable from Shuman in that, according to the present methods, topoisomerase covalently links both strands of two nucleotide sequences at the position where the sequences are joined.

It response to Applicants' previous Amendment, it was stated in the Office Action that Shuman describes linking a polynucleotide to a vector using a topoisomerase, wherein the sequences are linked in one strand, and transforming the nicked recombinant nucleic molecule into bacteria, which eliminate the nick. It is stated that, since the claims recite the term "comprising", Shuman meets the requirements of the claims because, following introduction into bacteria, the recombinant nucleic acid molecules of Shuman would not be expected to have a nick at the position where the sequences were joined.

As discussed in the telephone conference with the Examiner, however, the claims recite that the "topoisomerase covalently links both strands" of the first and second ds nucleotide sequences. There is nothing in Shuman or in the art of record that would indicate that bacteria utilize a topoisomerase to 'repair' a nick in an exogenously introduced nucleic acid molecule. As such, the claim subject matter is distinguishable from repairing a nick in a bacteria in that the claims recite that "the topoisomerase" covalently links both strands of at least one end of the first and second ds nucleotide sequences to generate a ds recombinant nucleic acid molecule does not contain a nick in either strand at the position where the ds nucleotide sequences are joined.

For the above reasons, it is submitted that the claimed methods, which are directed to the use of a topoisomerase to generate a ds recombinant nucleic acid molecule lacking a nick at the position at which two ds nucleotide sequences are joined, are novel over Shuman. Accordingly, it is respectfully requested that the rejection of the claims as anticipated by Shuman be removed.

The rejection of claims 32 to 34 and 36 under 35 U.S.C. § 103(a) as allegedly obvious over Shuman is respectfully traversed.

Shuman is applied for the reasons set forth above. It is acknowledged in the Office Action that Shuman does not teach using a third ds nucleotide sequence, but alleged that the skilled artisan would have been motivated to further bind a third ds nucleotide sequence to generate a desired construct. As discussed above, however, the claimed methods are distinguishable from Shuman in providing a method for using a topoisomerase to covalently link both strands of at least one end of the first ds nucleotide sequence to both strands of at least one end of the second ds nucleotide sequence, thereby generating a ds recombinant nucleic acid molecule that does not have a nick at the position of the joined ends. As such, even if one of ordinary skill in the art, viewing Shuman, would have been motivated to link three ds nucleotide sequences, the artisan would not have obtained a ds recombinant nucleic acid molecule in which a topoisomerase covalently links at least one end of a first ds nucleotide sequence to both strands of one end of a second ds nucleotide sequence, according to the present methods. Accordingly, it is submitted that the claimed invention would not have been obvious in view of Shuman and, therefore, respectfully requested that the rejection of claims 32 to 34 and 36 as obvious over Shuman be removed.

The rejection of claims 6, 7, 11, 15 to 24, 27 and 35 under 35 U.S.C. § 103(a) as allegedly obvious in view of Shuman in view of Yarovinsky is respectfully traversed.

Shuman is applied as discussed above. Yarovinsky is applied as describing topoisomerase activated oligonucleotide adapters for covalently binding sequences. It is stated in the Office Action that the skilled artisan would have been motivated to apply Yarovinsky's topoisomerase adapted vectors to the method of Shuman in order to bind amplified sequences into vectors.

As discussed above, however, the claimed invention is distinguishable from Shuman in providing a method of using topoisomerase to covalently link both strands of at least one end of the first ds nucleotide sequence to both strands of at least one end of the second ds nucleotide sequence, thereby generating a ds recombinant nucleic acid molecule that does not have nick at the position of the joined ends. Yarovinsky does not describe a method of generating a ds recombinant nucleic acid molecule lacking a nick. Referring to Figure 1 (lower panel) of Yarovinsky, the topoisomerase activated adapter (lower panel, left) can be contacted with a target nucleic acid (exemplified as having a 3'dAMP overhang; lower panel, right), wherein the topoisomerase can covalently link the 3' terminus of the adapter to the 5' terminus of the target nucleic acid. As is evident, however, a nick will remain between the 5' terminus of the adapter (at the end containing the topoisomerase) and the 3' terminus of the target nucleic acid. As such, it is submitted that the claimed methods would not have been obvious over the cited references, whether considered alone or in combination, and, therefore, respectfully requested that the rejection of claims 6, 7, 11, 15 to 24, 27 and 35 as obvious over Shuman in view of Yarovinsky be removed.

The rejection of claims 42 and 43 under 35 U.S.C. § 103(a) as allegedly obvious over Shuman in view of Seed et al. is respectfully traversed.

Shuman is applied as discussed above. The Seed et al. reference is applied as describing a T7 suppressor gene in an expression vector. It is stated in the Office Action that one of ordinary skill in the art would have been motivated to apply Shuman's method of construction to

express the T7 suppressor gene of Seed et al. in order to express and produce T7 suppressor, which can be used for diagnostic and therapeutic purposes.

As discussed above, however, the claimed invention is distinguishable from Shuman in providing a method for using a topoisomerase to covalently link both strands of at least one end of the first ds nucleotide sequence to both strands of at least one end of the second ds nucleotide sequence to generate a ds recombinant nucleic acid molecule that does not have a nick at the position of the joined ends. Seed et al. also do not describe a method of generating a ds recombinant nucleic acid molecule lacking a nick, according to the present invention. Instead, as stated in the Office Action, Seed et al. describe a T7 suppressor gene and expressing the T7 suppressor. As such, it is submitted that the claimed methods would not have been obvious over Shuman in view of Seed et al. and, therefore, is respectfully requested that the rejection of claims 42 and 43 as obvious over Shuman in view of Seed et al. be removed.

The rejection of claims 46 to 48 under 35 U.S.C. § 103(a) as allegedly obvious over Shuman in view of Trono et al. is respectfully traversed.

Shuman is applied as discussed above. The Trono et al. reference is applied as describing attaching a histidine tag to DNA. It is stated in the Office Action that one of ordinary skill in the art would have been motivated to apply the teaching of a histidine tag by Trono et al. to an expression system as described by Shuman in order to purify an expressed protein.

As discussed above, however, the claimed methods are distinguishable from Shuman in providing a method of using topoisomerase to covalently link both strands of at least one end of the first ds nucleotide sequence to both strands of at least one end of the second ds nucleotide sequence to generate a ds recombinant nucleic acid molecule that does not have a nick at the position of the joined ends. Trono et al. also do not describe a method of using topoisomerase to generate a ds recombinant nucleic acid molecule lacking a nick, according to the present invention. Instead, as stated in the Office Action, Trono et al. describe a histidine tag and its use

In re Application of:

Carrino et al.

Application No.: 10/014,128

Filed: December 7, 2001

Page 18

PATENT

Atty. Docket No.: INVIT1290-2


for purifying an expression product. As such, it is submitted that the claimed methods would not have been obvious over Shuman in view of Trono et al. and, therefore, is respectfully requested that the rejection of claims 46 to 48 as obvious over Shuman in view of Trono et al. be removed.

In view of the amendments and the above remarks, it is submitted that the claims are in condition for allowance, and a notice to that effect is respectfully requested. The Commissioner is authorized to charge Deposit Account No. 07-1896 if any fee is deemed necessary.

The Examiner is invited to contact Applicants' undersigned representative if there are any questions relating to this application.

Respectfully submitted,

Date: December 16, 2004



Richard J. Imbra

Reg. No. 37,643

Telephone: (858) 677-1496

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
**USPTO CUSTOMER NO. 28213**

FORM PTO-1449  
U.S. Department of Commerce Patent and  
Trademark Office

NOV 04 2002

Docket No.:  
INVIT1290-2

Attachment of #9  
Application No.:  
10/014,128

Applicants: Carrino et al.

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Filing Date:  
December 7, 2001

Group Art Unit:  
1645

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>[Signature]</i>	US 6,277,632 B1	08/21/01	Harney			
<i>[Signature]</i>	US 6,340,595 B1	01/22/02	Vogels et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION, (YES/NO)
	WO 97/48716	12/24/97	PCT			
	WO 98/56943	12/17/98	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	NONE

COPY

EXAMINER

*[Signature]*

DATE CONSIDERED

2/2/04

EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.